Dr. David A. Rosenberg, M.D.
Neurology (Neurology Physician)
- Medicare participating
At a glance
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 58
Licensed in California since 1980, according to the Medical Board of California. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Neurology Physician primary
CA license G42241 (first issued 1980; current)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Medicare patients and services
- Medicare patients, 2024
- 58
- Services billed
- 346
- Patients’ average age
- 79
| Service | Times | Patients |
|---|---|---|
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 202 | 44 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 74 | 29 |
| Critical care, first 30-74 minutes | 56 | 38 |
| Critical care, each additional 30 minutes | 46 | 29 |
| Measurement of brain wave activity (eeg), awake and drowsy | 23 | 17 |
| Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | 18 | 17 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Payments from drug and device companies
In 2025, 3 companies reported 3 payments worth $77.90 in total to this clinician.
| Merz North America, Inc. | $37.06 |
|---|---|
| Lilly USA, LLC | $20.66 |
| Galderma Laboratories, L.P. | $20.18 |
| Food and Beverage | $77.90 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 5 industry-funded studies in 2025, from 4 companies. The companies reported $326,727 in research payments for these studies, mostly to the institutions running them.
- A Study to Evaluate the Safety and Efficacy of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ≥60 Years of Age
ModernaTX, Inc. · Completed · NCT05127434 - ITI-1284-101
Iti, Inc. (d/b/a Intra-cellular Therapies, Inc.) - A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-2)
E.r. Squibb & Sons, L.l.c. · Recruiting · NCT06126224 - ITI-1284-201
Iti, Inc. (d/b/a Intra-cellular Therapies, Inc.) - Study of BOTOX Injections in Prevention of Migraine in Adult Participants With Episodic Migraine
AbbVie Inc. · Terminated · NCT05028569
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.